Frontline Nab-Paclitaxel/Gemcitabine in Metastatic Pancreatic Cancer

Gerrit zur Hausen, MSc
Published: Thursday, Sep 29, 2016


Gerrit zur Hausen, MSc, clinical trial manager, Epidemiologe, Institut für Klinisch-Onkologische Forschung, discusses a trial exploring frontline treatment with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic adenocarcinoma who have high-bilirubin levels.

The multicenter observational German study, titled QoliXane, is assessing quality of life and therapy data, zur Hausen explains. Researchers are also collecting available tumor tissues for further analyses. In the current interim analysis, patients with high baseline bilirubin level were studied.

Results showed that approximately 9% to 10% of the patients enrolled in the study had a high baseline bilirubin level. Seventy percent of these patients started therapy at a normal dose, while the remaining 30% started at a lower dose level. Additionally, more than half of these patients received a secondary intervention, including stenting or bile duct anastomosis, he adds.
SELECTED
LANGUAGE

Gerrit zur Hausen, MSc, clinical trial manager, Epidemiologe, Institut für Klinisch-Onkologische Forschung, discusses a trial exploring frontline treatment with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic adenocarcinoma who have high-bilirubin levels.

The multicenter observational German study, titled QoliXane, is assessing quality of life and therapy data, zur Hausen explains. Researchers are also collecting available tumor tissues for further analyses. In the current interim analysis, patients with high baseline bilirubin level were studied.

Results showed that approximately 9% to 10% of the patients enrolled in the study had a high baseline bilirubin level. Seventy percent of these patients started therapy at a normal dose, while the remaining 30% started at a lower dose level. Additionally, more than half of these patients received a secondary intervention, including stenting or bile duct anastomosis, he adds.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x